A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Onapristone (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ONAWA; Onward 203
Most Recent Events
- 31 Mar 2022 Status changed from recruiting to completed.
- 09 Dec 2021 According to a Context Therapeutics media release, results from this trial were presented during the 2021 San Antonio Breast Cancer Symposium (SABCS).
- 09 Dec 2021 Positive results published in the Context Therapeutics Media Release.